| CATEGORY: SMALL CAPS NEWS SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY |
Ark sees progress on cancer side effects |
|
Mon 20 Feb 2006
|
LONDON (SHARECAST) - Ark Therapeutics has unveiled what it claims is a way of cutting drastically the side effects of current cancer treatments.
The company says its latest reasearch showed its DNA-based drug-targeting technology Scavidin to be highly effective in stopping tumour development using only one tenth of the usual dose, meaning current doses of radiation and chemotherapy treatments could could substantially reduced.
"These results indicate that Scavidin has the potential both to improve the therapeutic effect and to reduce the unpleasant side-effects of a wide variety of drugs," chief executive Nigel Parker said in a statement, adding that Scavidin has potential uses across many disease areas.
|
|
| |
|
 |
Archived Stories |
 |
|
Front Page Stories |
|
|
